

Fact Sheet

ARK™ Gabapentin Assay

The ARK Gabapentin Assay is a homogeneous enzyme immunoassay intended for the quantitative determination of gabapentin in human serum or plasma on automated clinical chemistry analyzers. The measurements obtained are used in the monitoring of gabapentin levels to help ensure appropriate therapy.

Assay Characteristics

- Excellent precision, even in trough concentrations
- Fast and efficient routine monitoring for gabapentin
- · Liquid, ready-to-use reagents, calibrators and controls
- Storage at 2-8°C
- On-board stability for at least 60 days
- Does not contain any harmful preservatives, only ≤ 0.09% sodium azide

Background

Gabapentin [Neurontin®, 1-(aminomethyl)-cyclohexaneacetic acid] is indicated for use as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age and as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3-12 years. Gabapentin is also indicated for the management of postherpetic neuralgia in adults.

A therapeutic range for gabapentin has not been well established. A reference range of 2 μ g/mL to 20 μ g/mL has been proposed. Studies have suggested that optimal responses to gabapentin in patients with difficult-to-treat partial seizures are achieved at concentrations >2 μ g/mL or in a range of 4 to 11 μ g/mL, while others proposed a higher range of 6 to 21 μ g/mL. It has been reported that toxicity with gabapentin tends to occur with increasing frequency when serum concentrations exceed 25 μ g/mL. Interindividual variability may be influenced by dose-related saturable drug absorption, and hence, variable pharmacokinetic properties.





Properties of Gabapentin

Dose Adults & adolescents (ab 12) 3 x daily 300 mg, independent of meals;

Children (6-12) dosing according to body weight

Bioavailability 27 – 60% (inversely proportional to dose; fatty meals increase

bioavailability)

Peak level For low doses ~1 to 2 hours, for high doses 3 to 4 hours


Plasma protein binding Less than 3% Elimination Renal excretion

Metabolization No significant metabolization

Elimination half time 5 to 7 hours

Assay Precision

| | | | | Repeat | Reproducibility Total | | | |
|-------------------------|-----|--------------|------------|--------|--------------------------|--------|-------------|--------|
| Sample | N | M (µg/ml) | Within-Run | | | | Between Day | |
| | | | SD | CV (%) | SD | CV (%) | SD | CV (%) |
| ARK™ Gabapentin Control | | | | | | | | |
| LOW | 160 | 2.5 | 0.08 | 3.3 | 0.10 | 3.9 | 0.14 | 5.6 |
| MID | 160 | 7.9 | 0.21 | 2.6 | 0.26 | 3.3 | 0.35 | 4.4 |
| HIGH | 160 | 24.6 | 0.48 | 1.9 | 0.65 | 2.7 | 0.88 | 3.6 |
| Human Serum | | | | | | | | |
| LOW | 160 | 2.2 | 0.11 | 4.7 | 0.11 | 4.8 | 0.17 | 7.7 |
| MID | 160 | 7.3 | 0.58 | 2.4 | 0.25 | 3.4 | 0.33 | 4.6 |
| HIGH | 160 | 24.9 | 0.54 | 2.2 | 0.97 | 3.9 | 1.17 | 4.7 |



Order Information

| Product Description | Size | Order No. |
|----------------------------|---------------------|--------------|
| ARK™ Gabapentin Assay | 28 mL R1 & 14 mL R2 | 5025-0001-00 |
| ARK™ Gabapentin Calibrator | 1 x 4 mL & 5 x 2 mL | 5025-0002-00 |
| ARK™ Gabapentin Control | 6 x 4 mL | 5025-0003-00 |

